HE4 might be a more useful tumor biomarker to detect malignancy in patients with ovarian endometrioma when malignancy is suspected

Rius, Mariona; Fusté, Pere; Ros, Cristina; Martínez-Zamora, Angeles; deGuirior, C.; Gràcia, Meritxell; Mensión, Eduard; Carmona, Francisco

doi:10.1177/03000605211047701

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CA125 has certain limitations, it is still the most used classical marker in the clinical diagnosis of OTs (29). HE4 levels have high specificity, which is not affected by the menstrual cycle, hormonal treatment, or endometriosis, and can be used as an additional assessment to ultrasonography (30). In the present study, the critical values of CA125 and HE4 in premenopausal women were 35.1 U/mL and 72.8 pmol/L, respectively, and the critical values of CA125 and HE4 in postmenopausal women were 36.3 U/mL and 145.7 pmol/L, respectively, which are similar to previous studies (31–33).…”

Section: Discussionmentioning

confidence: 99%

Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours

Wang

et al. 2022

Acta Radiol

View full text Add to dashboard Cite

Background Ovarian tumors (OTs) are common gynecological tumors in women. It is very important to correctly distinguish benign and malignant OTs. Purpose To assess the diagnostic performance of the American College of Radiology (ACR) Ovarian-Adnexal Reporting and Data System (O-RADS) and evaluate the clinical value of O-RADS combined with serum carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) in differentiating benign from malignant OTs. Material and Methods A retrospective analysis was performed on 431 cases including pathology and clinical data. The receiver operating characteristic (ROC) curve was drawn, and sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Results In premenopausal women, O-RADS and O-RADS combined with serum CA125 and HE4 showed sensitivity at 92.2% and 94.8%, specificity at 91.8% and 93.4%, and accuracy at 91.9% and 93.8%, respectively. In postmenopausal women, the sensitivity of O-RADS, O-RADS combined with serum CA125 and HE4 was 94.8% and 95.8%, specificity was 83.9% and 93.6%, and accuracy was 90.5% and 95.6%, respectively. The sensitivity, specificity, and accuracy of O-RADS combined with CA125 and HE4 in premenopausal and postmenopausal women were higher than that of O-RADS ( P<0.05). Conclusion O-RADS has high diagnostic performance in OTs. When O-RADS is combined with CA125 and HE4 in the diagnosis of OTs, the sensitivity and specificity are improved, which is helpful to improve the diagnostic efficiency of OTs and has high clinical application value.

show abstract